Clinical Trials Logo

Toxemia clinical trials

View clinical trials related to Toxemia.

Filter by:

NCT ID: NCT03752489 Not yet recruiting - Sepsis Clinical Trials

Unsupervised Machine Learning for Clustering of Septic Patients to Determine Optimal Treatment

Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

The focus of this study will be to conduct a prospective, randomized controlled trial (RCT) at Cape Regional Medical Center (CRMC), Oroville Hospital (OH), and UCSF Medical Center (UCSF) in which a fluid treatment-specific algorithm will be applied to EHR data for the detection of severe sepsis. For patients determined to have a high risk of severe sepsis, the algorithm will generate automated voice, telephone notification to nursing staff at CRMC, OH, and UCSF. The algorithm's performance will be measured by analysis of the primary endpoint, reductions in in-hospital mortality.

NCT ID: NCT03473769 Not yet recruiting - Sepsis Clinical Trials

Sepsis Pre-Alert Monitoring Intervention: Study to Investigate Targeted Enhanced Monitoring for Sepsis

Start date: September 1, 2024
Phase: N/A
Study type: Interventional

Sepsis is a leading cause of death worldwide, and contributes to approximately 750,000 hospitalizations per year, a third of which may die. International guidelines recommend timely interventions, including cultures, fluid resuscitation and antibiotics. Following guideline bundles is associated with a decrease in mortality. Key to timely intervention is timely diagnosis. Using the Epic sepsis predictive analytic tool, investigators will trigger vital sign and delirium monitoring in patients determined to be at increased risk for developing future sepsis. The primary objective of this study is to demonstrate reduced mortality in patients for whom the pre-sepsis algorithm threshold is met, and who enhanced monitoring.

NCT ID: NCT03406494 Not yet recruiting - Sepsis Clinical Trials

Efficacy and Safety of a Multicomponent Physical Therapy Program in Mechanically Ventilated Patient With Sepsis

PTMVP
Start date: March 2018
Phase: N/A
Study type: Interventional

Despite of a remarkable decrease in overall mortality has been achieved following the International Guidelines for Management of Sepsis and Septic Shock since 2004,the short-and long-term outcomes remain poor in critically ill sepsis patients who had experienced prolonged ventilation in the Intensive Care Unit (ICU). The reason could be due to some subsequent complications developed in the ICU rather than original disease, e.g., ICU-acquired weakness (ICUAW), delirium, diaphragmatic dysfunction (DD) and acute gastrointestinal (GI) injury, which are still not fully recognized or dealt with in a majority of ICU settings across China. This study is aimed to examine whether a multi-component physical therapy (PT) program against these lethal ICU-related complications could reduce ICU 28-day mortality, improve independent functional status and 1-year survival in this subset of patients.

NCT ID: NCT03403062 Not yet recruiting - Neonatal SEPSIS Clinical Trials

Prognostic Value of Red Cell Distribution Width (RDW) in Neonatal Sepsis

Start date: February 2019
Phase:
Study type: Observational

1. Evaluate the relationship of RDW and severity and mortality in patients with neonatal sepsis . 2. Using RDW as a simple, inexpensive, applicable and rapid test to detect prognosis of neonatal sepsis .

NCT ID: NCT03379896 Not yet recruiting - Sepsis Clinical Trials

Study on Antigen-presenting Function of Gamma Delta T Cells in Sepsis and Its Molecular Mechanisms

Start date: January 4, 2018
Phase: N/A
Study type: Observational

Study on antigen-presenting function of gamma delta T cells in sepsis and its molecular mechanisms

NCT ID: NCT03367026 Not yet recruiting - Sepsis, Severe Clinical Trials

Reducing Elevated Heart Rate in Patients With Severe Sepsis by Ivabradine

REHSI
Start date: January 1, 2018
Phase: N/A
Study type: Interventional

REHSI is a prospective, multi-center, open label, randomized, controlled two arms, to evaluate the ability of ivabradine to reduce an elevated heart rate in septic shock patients. The primary end point is the reduction of heart rate within 24 hours. This trial will randomize 70 patients (men and women, aged ≥ 18 years) with newly diagnosed Septic Shock (despite adequate fluid resuscitation, were still requiring high-dose norepinephrine (NE) to maintain a mean arterial pressure (MAP) ≥65 mmHg , and had a tachycardia >100 beats per minute (bpm). Treatment period will last 4 days. All patients will be followed for up to six months.

NCT ID: NCT03354650 Not yet recruiting - Neonatal SEPSIS Clinical Trials

Epidemiology of Neonatal Sepsis in Neonatal Intensive Care Unit in Assiut University Children Hospital

Start date: January 1, 2018
Phase: N/A
Study type: Observational [Patient Registry]

Neonatal sepsis is an important cause of morbidity and mortality in the pediatric age group . It is one of the leading causes of death in the first 28 days of life both in the developed and developing countries.

NCT ID: NCT03308526 Not yet recruiting - Neonatal SEPSIS Clinical Trials

Prevailing Microorganisms Causing Neonatal Sepsis in Neonatal Intensive Care Unit (Prospective Study)Prevailing Microorganisms Causing Neonatal Sepsis in Neonatal Intensive Care Unit (Prospective Study)

PMCNSINICUPS
Start date: November 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

Prevailing microorganisms causing neonatal sepsis in neonatal intensive care unit of Assiut University children Hospital Methods prospective study conducted in the neonatal intensive care unit in Assiut university children hospital.

NCT ID: NCT03289312 Not yet recruiting - Sepsis Clinical Trials

Dissecting How Peripheral Lymphocytes Are Lost During Sepsis

SLL
Start date: January 11, 2018
Phase: N/A
Study type: Observational

There is an observational, clinical study. We recruit sepsis patients to investigate what drives peripheral lymphocyte loss in sepsis.

NCT ID: NCT03278730 Not yet recruiting - Sepsis Clinical Trials

Efficacy of Para-Tyrosine Supplementation on the Survival and Clinical Outcome in Patients With Sepsis

Start date: February 2025
Phase: Phase 2
Study type: Interventional

Meta-and ortho-Tyrosine are known markers of oxidative stress, while the physiological isomer, para-Tyrosine is suggested the antagonize the effects of meta- and ortho-Tyrosine. The changes in the serum levels of meta- and ortho-Tyrosine have been found to be paralel to that of the common sepsis markers. The hypothesis of the study is, that supplementation of para-Tyrosine (p-Tyr) in the early phase of sepsis may diminish some specific inflammatory procedures and thus may have a favourable impact on the disease progress, and consequently on the mortality.